Urology
Volume 75, Issue 6 , Pages 1254-1257 , June 2010

Determining Failure After Renal Ablative Therapy for Renal Cell Carcinoma: False-negative and False-positive Imaging Findings

  • Surena F. Matin

      Affiliations

    • Corresponding Author InformationReprint requests: Surena F. Matin, M.D., Department of Urology, Unit 1373, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

Received 15 November 2009 ,Accepted 5 January 2010.

References 

  1. Kummerlin I, ten Kate F, Smedts F, et al. Core biopsies of renal tumors: a study on diagnostic accuracy, interobserver, and intraobserver variability. Eur Urol. 2008;53:1219–1225
  2. Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol. 2007;189:429–436
  3. Lebret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: indications, accuracy, and results. J Urol. 2007;178:1184–1188
  4. Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety, and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178:379–386
  5. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29:747–754
  6. Liu L, Qian J, Singh H, et al. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med. 2007;131:1290–1297
  7. American Urological Association. Guideline for management of the clinical stage 1 renal mass. http://www.auanet.orgAccessed September 3, 2009
  8. Matsumoto ED, Watumull L, Johnson DB, et al. The radiographic evolution of radio frequency ablated renal tumors. J Urol. 2004;172:45–48
  9. Remer EM, Weinberg EJ, Oto A, et al. MR imaging of the kidneys after laparoscopic cryoablation. AJR Am J Roentgenol. 2000;174:635–640
  10. Svatek RS, Sims R, Anderson JK, et al. Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation. Urology. 2006;67:508–512
  11. Anderson JK, Shingleton WB, Cadeddu JA. Imaging associated with percutaneous and intraoperative management of renal tumors. Urol Clin North Am. 2006;33:339–352
  12. Matin SF, Ahrar K, Cadeddu JA, et al. Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study. J Urol. 2006;176:1973–1977
  13. Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441–450
  14. Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics. 2008;28:1325–1338
  15. Hecht EM, Israel GM, Krinsky GA, et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology. 2004;232:373–378
  16. Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol. 2008;179:1277–1281discussion 1281-1283
  17. Raman JD, Stern JM, Zeltser I, et al. Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging. J Urol. 2008;179:2142–2145
  18. Javadi S, Matin SF, Tamboli P, et al. Unexpected atypical findings on CT after radiofrequency ablation for small renal-cell carcinoma and the role of percutaneous biopsy. J Vasc Interv Radiol. 2007;18:1186–1191
  19. Lokken RP, Gervais DA, Arellano RS, et al. Inflammatory nodules mimic applicator track seeding after percutaneous ablation of renal tumors. AJR Am J Roentgenol. 2007;189:845–848
  20. Lin CH, Moinzadeh A, Ramani AP, et al. Histopathologic confirmation of complete cancer-cell kill in excised specimens after renal cryotherapy. Urology. 2004;64:590
  21. Matlaga BR, Zagoria RJ, Woodruff RD, et al. Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol. 2002;168:2401–2405comment 2409-2410
  22. Michaels MJ, Rhee HK, Mourtzinos AP, et al. Incomplete renal tumor destruction using radio frequency interstitial ablation. J Urol. 2002;168:2406–2410
  23. Rendon RA, Kachura JR, Sweet JM, et al. The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol. 2002;167:1587–1592
  24. Zlotta AR, Wildschutz T, Raviv G, et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol. 1997;11:251–258
  25. Klingler HC, Marberger M, Mauermann J, et al. “Skipping” is still a problem with radiofrequency ablation of small renal tumors. BJU Int. 2007;99:998–1001
  26. Hsu TH, Fidler ME, Gill IS. Radiofrequency ablation of the kidney: acute and chronic histology in porcine model. Urology. 2000;56:872–875

PII: S0090-4295(10)00035-X

doi: 10.1016/j.urology.2010.01.006

Urology
Volume 75, Issue 6 , Pages 1254-1257 , June 2010

Article Tools

* Image Usage & Resolution